The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

Tom H. Karlsen*, Nick Sheron, Shira Zelber-Sagi, Patrizia Carrieri, Geoffrey Dusheiko, Elisabetta Bugianesi, Rachel Pryke, Sharon J. Hutchinson, Bruno Sangro, Natasha K. Martin, Michele Cecchini, Mae A. Dirac, Annalisa Belloni, Miquel Serra-Burriel, Cyriel Y. Ponsioen, Brittney Sheena, Alienor Lerouge, Marion Devaux, Nick Scott, Margaret HellardHenkjan J. Verkade, Ekkehard Sturm, Giulio Marchesini, Hannele Yki-Järvinen, Chris D. Bryne, Giovanni Targher, Aviad Tur-Sinai, Damon Barrett, Michael Ninburg, Tatjana Reic, Alison Taylor, Tim Rhodes, Carla Treloar, Claus Petersen, Christoph Schramm, Robert Flisiak, Marieta Y. Simonova, Albert Pares, Philip Johnson, Alessandro Cucchetti, Isabel Graupera, Christos Lionis, Elisa Pose, Núria Fabrellas, Ann T. Ma, Juan M. Mendive, Vincenzo Mazzaferro, Harry Rutter, Helena Cortez-Pinto, Deirdre Kelly, Robyn Burton, Jeffrey V. Lazarus, Pere Ginès, Maria Buti, Philip N. Newsome, Patrizia Burra, Michael P. Manns

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Liver diseases have become a major health threat across Europe, and the face of European hepatology is changing due to the cure of viral hepatitis C and the control of chronic viral hepatitis B, the increasingly widespread unhealthy use of alcohol, the epidemic of obesity, and undiagnosed or untreated liver disease in migrant populations. Consequently, Europe is facing a looming syndemic, in which socioeconomic and health inequities combine to adversely affect liver disease prevalence, outcomes, and opportunities to receive care. In addition, the COVID-19 pandemic has magnified pre-existing challenges to uniform implementation of policies and equity of access to care in Europe, arising from national borders and the cultural and historical heterogeneity of European societies. In following up on work from the Lancet Commission on liver disease in the UK and epidemiological studies led by the European Association for the Study of the Liver (EASL), our multidisciplinary Commission, comprising a wide range of public health, medical, and nursing specialty groups, along with patient representatives, set out to provide a snapshot of the European landscape on liver diseases and to propose a framework for the principal actions required to improve liver health in Europe. We believe that a joint European process of thinking, and construction of uniform policies and action, implementation, and evaluation can serve as a powerful mechanism to improve liver care in Europe and set the way for similar changes globally.

Original languageEnglish
Pages (from-to)61-116
Number of pages56
JournalThe Lancet
Volume399
Issue number10319
Early online date2 Dec 2021
DOIs
Publication statusPublished - 1 Jan 2022

Keywords

  • liver disease
  • premature mortality
  • Europe

Fingerprint

Dive into the research topics of 'The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality'. Together they form a unique fingerprint.

Cite this